Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rempex Pharmaceuticals announces $67.5mm Series B

Executive Summary

Start-up Rempex Pharmaceuticals Inc. (developing therapeutics aimed at antibiotic resistance) completed the first closing of a Series B financing that could reach $67.5mm. Participating in the round were new investors Frazier Healthcare Ventures and Vivo Ventures, along with returning shareholders SV Life Sciences, OrbiMed Advisors, and Adams Street Partners.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies